Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00923052 · ClinicalTrials.gov registry record

The Natural History of Solid Organ Cancer Stem Cells (SOCSC)

A clinical trial, sponsored by National Cancer Institute (NCI).

Terminated
Registry status
190
Enrollment target

NCT00923052: Clinical Trial study, sponsored by National Cancer Institute (NCI).

NCT00923052 is a clinical trial that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 190 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00923052 was terminated before completion, sponsored by National Cancer Institute (NCI).

TERMINATED
Registry status
190 participants
Enrollment target

Study Summary

Background: * Researchers are trying to learn what causes certain types of cancer to spread to other organs in the body (metastasis). Cancer tumors may produce a very small number of specific cells (cancer stem cells) that cause the tumors to grow in other organs throughout the body. * By examining cancer tumor tissue, normal tissue, blood, bone marrow, and other body fluids, researchers may determine whether these samples contain cancer stem cells. Cancer stem cells may provide information on whether the cancer will come back or spread before other routine x-ray studies or lab tests indicate its presence. Objectives: * To acquire a collection of solid organ cancer stem cells for future study. * To analyze solid organ cancer stem cells from various types of cancer on a genetic level. * To determine if solid organ cancer stem cells are present in the blood or bone marrow. Eligibility: * Patients 16 years of age and older who have solid organ cancer (cancer in the liver, colon, rectum, anus, pancreas, stomach, breast, skin, muscles, fat, connective tissue, uterus, ovary, cervix, vagina, vulva, or inner lining of the abdomen) or a precancerous growth, and who are scheduled to have a biopsy or surgery to remove the cancer as part of their treatment. Design: * This is a prospective trial designed to procure solid organ cancer stem cells before either surgery or biopsy. * All patients registered to this trial will undergo surgery to extirpate their cancer in the NCI * Prior to surgery or biopsy, 8 tablespoons of blood will be drawn. * During the surgery or biopsy, a sample of normal tissue will be removed along with the cancerous or precancerous tissue. If separate consent is given, samples of bone marrow will also be taken. * After discharge, patients will return to the clinic for routine visits every month for the first 3 months following surgery, and then about every 3 months for 2 years, and then every 6 months for 3 years. During the visits, patients will have

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2009-02-09
Est. Completion 2015-05-07
National Cancer Institute (NCI)

3,257 total trials

Why NCT00923052 stopped before completion

NCT00923052 is an observational study that tracks outcomes without assigning an intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00923052 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00923052 about?

NCT00923052 is a clinical study titled "The Natural History of Solid Organ Cancer Stem Cells (SOCSC)". Background: * Researchers are trying to learn what causes certain types of cancer to spread to other organs in the body (metastasis). Cancer tumors may produce a very small number of specific cells (cancer stem cells) that cause the tumors to grow in other organs throughout the body. * By examining...

What is the current status of trial NCT00923052?

This trial is currently terminated. The enrollment target is 190 participants. The study started on 2009-02-09. Estimated completion is 2015-05-07.

Who is sponsoring clinical trial NCT00923052?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03257033 · 190 participants · Phase 3

    Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

  • NCT03642028 · 190 participants · Phase 4

    Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

  • NCT04015609 · 190 participants · NA

    Psychotherapy Intervention for Latinos With Advanced Cancer

  • NCT04284397 · 190 participants · Early Phase 1

    Identification of Critical Thermal Environments for Aged Adults

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00923052, the US trial registry maintained by the National Library of Medicine. NCT00923052 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.